Oncocyte Announces Major Steps in Clinical Trial Progress
Oncocyte Corp., a leader in diagnostics technology, is excited to share its advancements toward initiating a significantly important clinical trial. This trial will serve as a crucial requisite for gaining regulatory approval for a groundbreaking organ transplant rejection monitoring test kit.
Key Developments in the Clinical Trial
Oncocyte's clinical trial design has been completed, and it has received a green light from a prominent central institutional review board (IRB). The IRB will oversee safety and ethical compliance across various participating hospitals, which is critical for the integrity of the trial.
The company is poised to welcome three of the top ten U.S. transplant centers as participants. This is significant since these centers account for nearly 10% of the annual organ transplant volume in the United States. Oncocyte is anticipating the wealth of expertise and diverse patient demographics these esteemed centers will bring to the trial.
Market Potential for Transplant Rejection Testing
Transplant rejection testing is a thriving market segment generating approximately $500 million in the U.S. annually, dominated by a few large central laboratories. Oncocyte’s innovation aims to enable local transplant centers to conduct this essential testing within their facilities, fostering a more sustainable and accessible model of care for communities. On a global scale, the market for transplant rejection tests is estimated to exceed $1 billion yearly.
Excitement from the Transplant Community
“The transplant community is eager to adopt in-house testing solutions. Several of the leading transplant centers in the U.S. are enthusiastic participants in our journey to bring this test kit to market,” expressed Oncocyte CEO Josh Riggs. The company has set ambitious milestones, and they are looking forward to announcing these developments to the public.
Riggs added, “Our collaboration with Bio-Rad, announced last year, was geared towards this moment. We are entering this trial phase with substantial momentum, and we are targeting the submission of our complete data package later this year.”
Upcoming Announcements
Oncocyte also plans to introduce its National Principal Investigator (NPI) in the near future. This leading transplant expert will be showcased through a conference call aimed at promoting dialogue with the medical and investment communities.
Understanding Oncocyte's Pathway to FDA Approval
The forthcoming clinical trial is the only step required to secure FDA approval for the release of Oncocyte's inaugural test kit. The company is pursuing the Class II de novo pathway, which is typically designated for lower-risk medical devices. This contrasts with Class III devices, which often relate to life-support technologies.
Oncocyte has already succeeded in obtaining Clinical Laboratory Improvement Amendments (CLIA) validation as well as reimbursement from the Centers for Medicare & Medicaid Services (CMS) for the lab-developed variant of their test. This foundation underscores the company's commitment to compliance and quality.
Final Preparations with FDA and Expectations
Oncocyte is gearing up for its second and final Q-Submission (Q-Sub) meeting, a formal procedure to solicit feedback from the FDA ahead of their product authorization application. Reviews from the FDA during the first Q-Sub meeting in December were productive and collaborative, setting a positive tone for proceeding discussions.
Dr. Johnson Chiang, Chief Technology Officer of Oncocyte, remarked, “The constructive engagement we've had with the FDA has been promising, and we anticipate our upcoming final Q-Sub meeting with optimism. Whether through our clinical trial or our prior interactions, we're laying a solid groundwork for our FDA submission.”
Innovative Testing Technology
The essence of Oncocyte's kitted test lies in its measurement of a specific molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). This innovative biomarker has emerged over the past decade as a reliable indicator of transplant rejection, thanks to the dedication of Oncocyte's scientific teams in both Germany and the U.S. The company is on a path to revolutionize how this technology can be accessed in the market.
About Oncocyte
Oncocyte is a forward-thinking diagnostics technology firm committed to broadening access to innovative molecular diagnostic approaches that enhance patient care outcomes. Investors interested in the company can explore more about their initiatives and vision at their web portal.
Frequently Asked Questions
What is Oncocyte's recent clinical trial update?
Oncocyte has progressed significantly by obtaining central IRB approval and is set to initiate a clinical trial with key U.S. transplant centers.
What is the potential market for transplant rejection testing?
The U.S. market for transplant rejection testing is valued at around $500 million annually, with global prospects exceeding $1 billion.
How does Oncocyte's test kit benefit local transplant centers?
The test kit aims to allow local transplant centers to conduct testing in-house, enhancing revenue and sustainability for these facilities.
What is the Class II de novo pathway?
This pathway is a regulatory route for lower-risk medical devices, which Oncocyte is pursuing for its transplant rejection test kit.
Who will be the National Principal Investigator for Oncocyte's trial?
Oncocyte plans to announce the identity of its NPI soon, introducing a crucial expert in transplant care to the public.
